WEST-WARD PHARMS INT
GenericsWEST-WARD PHARMS INT is a generic drug manufacturer focused on Oncology, Gastroenterology, Infectious Disease.
WEST-WARD PHARMS INT's Key Drugs
WEST-WARD PHARMS INT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
WEST-WARD PHARMS INT's Recent FDA Approvals
New NDA/BLA approvals for WEST-WARD PHARMS INT over the last two years — novel drugs only, excluding generics and label supplements.
WEST-WARD PHARMS INT's Therapeutic Areas
WEST-WARD PHARMS INT's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
WEST-WARD PHARMS INT's Top Competitors
WEST-WARD PHARMS INT's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
WEST-WARD PHARMS INT Pipeline Snapshot
Active clinical trials for WEST-WARD PHARMS INT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1971-10-20
- Latest
- 2025-12-22
- Applications
- 18